The first commercial volumetric printing equipment in China, OrganSEC. On August 29th, it was reported that at the first Green Key Volume Printing Technology Application Forum recently held at the Panyu Campus of Guangzhou Medical University, Guangzhou Medical University, together with relevant units, officially released the first commercial volume bioprinting equipment in China, OrganSEC. This device solves the problems of slow printing speed and low cell survival rate in conventional layer by layer printing, and its technical indicators have reached the international first-class level. Volume bioprinting technology is a volume slicing and light intensity compensation algorithm developed based on CT imaging principles. It can project the longitudinal and two-dimensional slices of a three-dimensional object onto a rotating printing bottle through a specific algorithm, allowing the light cured bio ink and cells in the printing bottle to simultaneously form a three-dimensional object from all directions. The printing method is three-dimensional molding Xie Maobin, the head of the R&D team and a professor at the School of Biomedical Engineering, Guangzhou Medical University, introduced that OrganSEC adopts a backprojection algorithm based on holographic imaging projection technology and CT imaging principles. The three-dimensional (active) structure with centimeter level dimensions of the device can be printed in just 10 to 120 seconds. This greatly improves printing efficiency and cell survival rate. The cell survival rate of the device after printing is greater than 95%, indicating high cell activity. With this device, printing of cells can be achieved under visible light and ambient temperature conditions. It is reported that OrganSEC is mainly developed for the organoid market, suitable for organoid preparation, organoid based personalized drug therapy for tumors, and organoid based drug screening, providing personalized drug guidance for cancer patients. When patients experience tumor metastasis and recurrence, in order to find a more precise medication plan, doctors will perform organ sample culture and drug screening on the patient's tumor samples. In the past, this type of organ sample cultivation required at least two to three weeks, but now if OrganSEC equipment is used, it may only take 10 seconds to complete Xie Maobin revealed that they are currently developing screening guidelines for personalized medication based on organoid tumors. The guide is mainly used to guide doctors in medication. On the forum, Xie Maobin's R&D team also launched the first domestically developed volume printing equipment control software (Haomiao) and released six commercial bioprinting inks. Haomiao software highly integrates functions such as control, calculation, and parameter adjustment, and has three major features: rich printing model library, real-time online slicing, and multi file printing, filling the gap in volume printing control software in China. (New Society)